Life Sciences Opportunities in India & China: From Innovation to Commercialization
30 de setembro de 2009
China and India are emerging as major players in the life sciences industry. Both countries have a wealth of top talent as well as rapidly-improving resources for the industry. Both countries also constitute important current and potential markets for drugs, devices and diagnostics, and are also projected to be major sources of innovation in the not-too-distant future. This panel will explore the significant opportunities in China and India, in terms not only of expanding operations to both countries, but also in terms of working with innovative companies that originate from China and India.
Moderator:
- David A. Charapp, Special Counsel, Foley & Lardner LLP
Painelistas:
- Stephen A. Bent, Partner, Foley & Lardner LLP
- Friedhelm Blobel, Ph.D., President, CEO, Director, SciClone Pharmaceuticals
- Kim Kamdar, Ph.D., Principal at Domain Associates
- Sanjay Shukla, M.D., M.S., Chief Executive Officer, RxMD
Informações relacionadas
December 12, 2025
Health Care Law Today
Eleventh Circuit Hears Oral Argument in Landmark Constitutional Challenge to False Claims Act’s Qui Tam Provisions
On December 12, the U.S. Court of Appeals for the Eleventh Circuit heard oral argument in U.S. ex rel. Zafirov v. Florida Medical…
11 de dezembro de 2025
Pontos de vista de Foley
Riscos antitrust e estratégias de conformidade na gestão de portfólios de propriedade intelectual
Este artigo analisa como a gestão do portfólio de propriedade intelectual pode, simultaneamente, promover a inovação e apresentar potencial...
11 de dezembro de 2025
Pontos de vista de Foley
CARB divulga regulamentos propostos para SB 261 e 253
Em 9 de dezembro de 2025, o Conselho de Recursos Atmosféricos da Califórnia (CARB) divulgou o texto regulamentar proposto para as regulamentações iniciais...